A machine learning model can use patient-reported data and remote therapeutic monitoring to accurately assess low disease ...
Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced interim safety ...
New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, ...
Sonoma Biotherapeutics has announced positive interim results from its ongoing phase 1 Regulate-RA trial evaluating ...
KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid ...
Kymera Therapeutics recently presented new preclinical data for its oral IRF5 degrader KT-579 at the American College of Rheumatology 2025 meeting, showing disease-modifying activity in lupus and ...
Inflammatory arthritis resulting from immune checkpoint inhibitor use is immunologically unique and likely driven by T cells ...
KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to appro ...
The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...
Your mouth's health significantly impacts your entire body, new research reveals. Poor oral hygiene is linked to serious ...
New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...
A meta-analysis reveals that oral Janus kinase inhibitors elevate LDL and HDL cholesterol, underscoring the need for lipid monitoring in patients receiving JAK inhibitor therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback